Pruritus Related to Trastuzumab and Pertuzumab in HER2+ Breast Cancer Patients

PURPOSE: The combination of trastuzumab and pertuzumab (HP) as part of a taxane-based regimen has shown benefit in the adjuvant and metastatic HER2+ breast cancer setting. In the CLEOPATRA trial, pruritus was reported in 11-17.6% of patients. The clinical phenotype and potential treatment strategies...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Stephanie, Dusza, Stephen, Quigley, Elizabeth, Haliasos, Helen, Markova, Alina, Marchetti, Michael, Moy, Andrea, Dang, Chau, Modi, Shanu, Lake, Diana, Noor, Sarah, Lacouture, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168468/
https://www.ncbi.nlm.nih.gov/pubmed/37163123
http://dx.doi.org/10.21203/rs.3.rs-2679676/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168468/
https://www.ncbi.nlm.nih.gov/pubmed/37163123
http://dx.doi.org/10.21203/rs.3.rs-2679676/v1

Ejemplares similares